HER2 Positive Rectal Adenocarcinoma
1 clinical trials · Condition
◉ Watch HER2 Positive Rectal Adenocarcinoma
| Record | Firm | Date |
|---|---|---|
| A Study of Tucatinib and Trastuzumab in People With Rectal Cancer (NCT05672524) | Memorial Sloan Kettering Cancer Center | 2022-12-30 |
Track HER2 Positive Rectal Adenocarcinoma automatically
Every clearance here is in the API, with alerts when new ones post.